McKinsey to pay $650 million over role in OxyContin epidemic
McKinsey agreed to pay $650 million as part of a deferred prosecution agreement, according to court documents filed Friday. As part of the agreement, McKinsey will "not do any work related to the marketing, sale, promotion or distribution of controlled substances" and will not contest the facts of the government's criminal charges.